Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 8/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680222 | 1.00 | TRPA1 (0.47) | TRPA1CTSSCTSKPTGESCTSB | |
| SCHEMBL14726008 | 0.85 | HTRA1 (0.42) | CTSKPTGESCTSBCTSLFFAR1 | |
| SCHEMBL5778861 | 0.84 | FFAR1 (0.46) | CTSKPTGESCTSBCTSLFFAR1 | |
| SCHEMBL12807428 | 0.84 | FFAR1 (0.41) | CTSSCTSKCTSBCTSLFFAR1 | |
| SCHEMBL13309005 | 0.83 | CTSK (0.51) | CTSSCTSKCTSBCA2CTSL | |
| SCHEMBL10192143 | 0.83 | CTSK (0.51) | CTSSCTSKCTSBCA2CTSL | |
| SCHEMBL645461 | 0.83 | ALDH1A1 (0.49) | CTSKCA2ACEKLK5 | |
| SCHEMBL12735813 | 0.83 | ALDH1A1 (0.49) | CTSKCA2ACEKLK5 | |
| SCHEMBL10795527 | 0.82 | CTSS (0.52) | CTSSCTSKPTGESCTSBCA2 | |
| SCHEMBL4499875 | 0.80 | CTSS (0.53) | CTSSCTSKPTGESCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1539727-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060004073-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6949538-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1539727-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040116400-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004006865-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | TRPA1 4878/4885CTSS 1743/4885CTSK 1412/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | TRPA1 4838/4885CTSS 1434/4885CTSK 1326/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | TRPA1 4838/4885CTSS 1434/4885CTSK 1326/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | TRPA1 4838/4885CTSS 1434/4885CTSK 1326/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | TRPA1 4838/4885CTSS 1434/4885CTSK 1326/4885 |
| US-20060004073-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | TRPA1 4832/4885CTSS 1307/4885CTSK 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.